Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Genitourinary tumours

138MO - A randomized study to compare outcomes of intravesical chemohyperthermia with mitomycin C vs intravesical BCG for intermediate and high risk non-muscle invasive bladder cancer (NMIBC)

Date

02 Dec 2022

Session

Mini Oral session: Genitourinary tumours

Topics

Therapy;  Cancer Control Principles

Tumour Site

Urothelial Cancer

Presenters

Karandeep Guleria

Citation

Annals of Oncology (2022) 33 (suppl_9): S1485-S1494. 10.1016/annonc/annonc1124

Authors

K. Guleria1, R. Sood1, H. Goel1, U. SHARMA2, A. Singla1

Author affiliations

  • 1 Department Of Urology And Renal Transplant, ABVIMS & Dr RML Hospital, 110001 - New Delhi/IN
  • 2 Urology & Renal Transplantation, ABVIMS & RML HOSPITAL, NEW DELHI/IN

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 138MO

Background

With the global shortage of bacillus Calmette-Guerin (BCG) coupled with the high recurrence rates of NMIBC, newer adjuvant intravesical treatment options are required. Although intravesical BCG remains the gold standard, the use of chemohyperthermia (CHT) as an alternative treatment is expanding all over the world. This study looks into the use of CHT with MMC as an alternative for BCG in NMIBC.

Methods

Between 2019 and 2021, 140 consenting NMIBC patients were randomised in a single centre study for 1-yr CHT (six weekly treatments and monthly maintenance treatments till 1 year) and 1-yr BCG immunotherapy (six weekly treatments and three weekly maintenance treatments at months 3, 6, and 12). Patients and physicians giving the interventions were aware of assignment. Follow up was done by 3 monthly cystoscopy and urine cytology. Adverse effects were graded by using the Modified Clavien Dindo Classification.

Results

The 12 month Recurrence Free Survival (RFS) was 97.10 % in the CHT group compared with 94.30 % in the BCG group (p = 0.53). No progression in the NMIBC was seen in CHT group whereas progression rate was 1.7% in BCG group. Regarding the side-effects, during the induction phase initially the side effects were more in the BCG group, but with the progression of the cycles the side effects of the CHT group increased, with the most common side effects being LUTS, UTI, Fever and Bladder spasms. The side effects during the maintenance phase were comparable between the CHT and BCG groups. All the side effects were classified as either grade 1 or grade 2 based on the Modified Clavien Dindo Classification. A concern is that the follow up period in this study was short and thus is underpowered. Furthermore, blinding of treatment for patients and physicians was impossible; this may have resulted in unavoidable bias.

Conclusions

CHT is a safe and effective treatment option in patients with intermediate- and high-risk NMIBC. A higher 12 month RFS in the CHT group was seen along with a comparable side effect profile. Based on the results above, CHT is an alternative option to intravesical BCG therapy as adjuvant treatment for intermediate and high-risk NMIBC.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.

  • Analytics cookies help us improve our website by collecting and reporting information on its usage.

  • We use marketing cookies to build a profile of you as a user through your actions on our site in order to better understand your interests and provide you with pertinent suggestions.